Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
The protein encoded by DOT1L is a histone methyltransferase that methylates lysine-79 of histone H3. Additionally we are shipping DOT1-Like, Histone H3 Methyltransferase (S. Cerevisiae) Kits (6) and DOT1-Like, Histone H3 Methyltransferase (S. Cerevisiae) Proteins (4) and many more products for this protein.
Showing 10 out of 78 products:
Human Polyclonal DOT1L Primary Antibody for ChIP, ICC - ABIN251529
Steger, Lefterova, Ying, Stonestrom, Schupp, Zhuo, Vakoc, Kim, Chen, Lazar, Blobel, Vakoc: DOT1L/KMT4 recruitment and H3K79 methylation are ubiquitously coupled with gene transcription in mammalian cells. in Molecular and cellular biology 2008
Show all 5 Pubmed References
Human Polyclonal DOT1L Primary Antibody for ICC, IF - ABIN251530
Vernimmen, Lynch, De Gobbi, Garrick, Sharpe, Sloane-Stanley, Smith, Higgs: Polycomb eviction as a new distant enhancer function. in Genes & development 2011
Human Monoclonal DOT1L Primary Antibody for IF, ELISA - ABIN566567
Phillips, Wildt, Comizzoli: Incidence of methylated histones H3K4 and H3K79 in cat germinal vesicles is regulated by specific nuclear factors at the acquisition of developmental competence during the folliculogenesis. in Journal of assisted reproduction and genetics 2016
findings demonstrate that DOT1L over-expression has important clinical significance in ovarian cancer and also clarify that it drives cell cycle progression through transcriptional regulation of CDK6 (show CDK6 Antibodies) and CCND3 (show CCND3 Antibodies) through H3K79 methylation
MLL (show MLL Antibodies)-AF4 spreading gene expression is downregulated by inhibitors of the H3K79 methyltransferase DOT1L.
our results identify DOT1L as a novel cofactor in N-Myc (show MYCN Antibodies)-mediated transcriptional activation of target genes and neuroblastoma (show ARHGEF16 Antibodies) oncogenesis. Furthermore, they characterize DOT1L inhibitors as novel anticancer agents against MYCN (show MYCN Antibodies)-amplified neuroblastoma (show ARHGEF16 Antibodies).
These results reveal a cooperative transcriptional activation mechanism of AEP (show LGMN Antibodies) and DOT1L and suggest a molecular rationale for the simultaneous inhibition of the MLL (show MLL Antibodies) fusion-AF4 complex and DOT1L for more effective treatment of MLL (show MLL Antibodies)-rearranged leukemia.
this indicates that DOT1L function, like MLL (show MLL Antibodies), does not completely rely on its methyltransferase activity. Nevertheless, the small molecule DOT1L inhibition is sufficient to block the proliferation of MLL (show MLL Antibodies) fusion-induced leukemia cells of murine and human origin
DOT1L may play a critical role in DNMT3A (show DNMT3A Antibodies)-mutant leukemia.
DOT1L, via dimethylated histone H3 (show HIST3H3 Antibodies) K79, facilitates histone H4 acetylation, which in turn regulates the binding of BRD4 (show BRD4 Antibodies) to chromatin in acute lymphoblastic leukemia.
study demonstrates the development of potent DOT1L inhibitors with novel scaffolds
these findings strongly support the contention that histone methyltransferase, DOT1L-associated epigenetic changes induced by HA play pivotal roles in miR-10 (show LILRB2 Antibodies) production leading to up-regulation of RhoGTPase and survival proteins.
Report drug formulation/delivery of DOT1L inhibitor pinometostat in leukemia.
We will highlight the structural basis of chromatin targeting of DOT1L through its cofactors and the role of DOT1L in repelling transcription repressive complexes during leukemia development.
DOT1L, via dimethylated histone H3 (show HIST3H3 Antibodies) K79, facilitates histone H4 (show HIST1H4H Antibodies) acetylation, which in turn regulates the binding of BRD4 (show BRD4 Antibodies) to chromatin in acute lymphoblastic leukemia.
Dot1l is a new epigenetic regulator of principal cells and intercalated cell differentiation and Atp6v1b1 (show ATP6V1B1 Antibodies) is a new transcriptional target of Dot1l.
results demonstrate that histone methylation, and in particular DOT1L-mediated H3K79me2 modification, drives cardiomyogenesis through the definition of a specific transcriptional landscape
Interference with DOT1L activity resulted in transcriptional activation of Atf4 (show ATF4 Antibodies) and Ddit3 (show DDIT3 Antibodies) accompanied by decreased levels of H3K79 dimethylation.
MLL1 and DOT1L cooperate with meningioma-1 to induce acute myeloid leukemia (show BCL11A Antibodies).
DOT1L has a role in inhibiting SIRT1 (show SIRT1 Antibodies)-mediated epigenetic silencing to maintain leukemic gene expression in MLL (show MLL Antibodies)-rearranged leukemia
Dot1L and H3K79 methylation play important roles in meiosis progression and are supposed to be associated with chromosome deacetylation of mouse oocytes.
The protein encoded by this gene is a histone methyltransferase that methylates lysine-79 of histone H3. It is inactive against free core histones, but shows significant histone methyltransferase activity against nucleosomes.
histone-lysine N-methyltransferase, H3 lysine-79 specific
, DOT1-like, histone H3 methyltransferase (S. cerevisiae)
, histone-lysine N-methyltransferase, H3 lysine-79 specific-like
, possible nucleosomal histone methylase
, DOT1-like protein
, DOT1-like, histone H3 methyltransferase
, histone H3-K79 methyltransferase
, histone methyltransferase DOT1L
, lysine N-methyltransferase 4
, DOT1-like histone H3 methyltransferase
, histone H3 methyltransferase DOT1